## Answer
(model generated chain of thought explanation)

Given the patient's symptoms, including gradual forgetfulness and withdrawal, difficulty with memory recall, incontinence, and recent episodes of urinary and fecal incontinence, along with physical examination findings such as hypertension, hyperlipidemia, and ventriculomegaly on MRI scan, these are indicative of Alzheimer's disease. The patient's age and the presence of physical symptoms also support this diagnosis.

The pharmacotherapy for Alzheimer's disease typically involves cholinesterase inhibitors (ChEIs) or memantine, which work by enhancing cholinergic neurotransmission in the brain to improve cognitive function.

- Donepezil (A) is a ChEI that increases acetylcholine levels and is commonly used as an adjunct therapy for patients with mild to moderate Alzheimer's disease.
- Thiamine (B) is a vitamin B1 supplement, which can be beneficial for individuals with chronic alcohol use disorder or Wernicke-Korsakoff syndrome but is not the primary treatment for Alzheimer's disease.
- Acetazolamide (C) is a carbonic anhydrase inhibitor that can improve cognitive function in some patients with Alzheimer's disease by reducing cerebral edema and improving cholinergic neurotransmission, but it is not considered a first-line treatment.
- Memantine (D) is a N-methyl-D-aspartate (NMDA) receptor antagonist that has been shown to slow the progression of cognitive decline in patients with mild to moderate Alzheimer's disease.

Therefore, considering the patient's diagnosis of Alzheimer's disease and the need for pharmacotherapy to manage symptoms and slow disease progression, Memantine would be the most appropriate choice.